Vaccinated people who were infected by the first omicron subvariants have four times greater protection than vaccinated people who were not infected. These results are part of a study that will be published today in the New England Journal of Medicine.
The study was led by Luís Graça, group leader at the Instituto de Medicina Molecular João Lobo Antunes (iMM) and Full Professor at the Faculty of Medicine of the University of Lisbon, and by Manuel Carmo Gomes, Associate Professor with Aggregation at the Faculty of Sciences of the University of Lisbon (Ciências ULisboa). Both researchers are members of the Technical Commission on Vaccination against COVID-19 (CTVC) of the Direção Geral de Saúde (DGS).
This is one of the first studies worldwide to analyze the probability of becoming infected with the subvariant currently in circulation in vaccinated people, by estimating the degree of protection conferred by infections with previous variants and using real-world data.
“Vaccinated people who were infected by omicron subvariants BA.1 and BA.2 have a protection against infection with subvariant BA.5, zithromax treat urinary tract infection in circulation since June, about four times greater than vaccinated people who were not infected at any time,” says Luís Graça, co-leader of the study.
“Infections in 2020 and 2021 that occurred through infection with earlier variants of the SARS-CoV-2 virus (ancestral lineage, alpha and delta variants) also confer protection against infection for the more recent omicron variant, although this protection is not as high as that of individuals infected with the BA.1 and BA.2 variants, at the beginning of 2022.”
“These results are very important because the adapted vaccines that are in clinical development and evaluation are based on the BA.1 subvariant of the virus, which was a dominant variant in infections in January and February 2022. Until now, it was not known what degree of protection this subvariant provides against the subvariant that is currently in circulation. These results show that this protection is very significant and allows us to anticipate the benefit of the adapted,” says Graça.
To carry out this study, the researchers had access to the registry of COVID-19 cases at Portugal’s national level. “We used the Portuguese national registry of COVID-19 cases to obtain information on all cases of SARS-CoV-2 infections in the population over 12 years of age residing in Portugal. The virus variant of each infection was determined considering the date of infection and the dominant variant at that time. We considered the infections caused by the first variants of omicron BA.1 and BA.2 together,” says Manuel Carmo Gomes.
“With these data, we analyzed the probability of a person that was previously infected to be reinfected with the current variant, which allowed us to calculate the percentage of protection provided by previous infections,” says João Malato, Ph.D. student in Luís Graça’s group and first author of the study.
Source: Read Full Article